

Analogs of the lignan pinoresinol as novel lead compounds for P-glycoprotein (P-gp) inhibitors

Jeronimo Laiolo, Tihomir Tomašič, D. Mariano A. Vera, Maria Laura González, Priscila A. Lanza, Samanta N. Gancedo, Ziga Hodnik, Lucija Peterlin Mašič, Danijel Kikelj, and Maria C Carpinella

ACS Med. Chem. Lett., **Just Accepted Manuscript** • DOI: 10.1021/acsmchemlett.8b00324 • Publication Date (Web): 21 Nov 2018

Downloaded from <http://pubs.acs.org> on November 21, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Analogs of the lignan pinoresinol as novel lead compounds for P-glycoprotein (P-gp) inhibitors

Jerónimo Laiolo,[†] Tihomir Tomašič,[§] D. Mariano A. Vera,[‡] María L. González,[†] Priscila A. Lanza,[‡]

Samanta N. Gancedo,[‡] Žiga Hodnik,[§] Lucija Peterlin Mašič,[§] Danijel Kikelj,^{§,*} María C. Carpinella^{*,†}

[†] *Research Institute of Natural Resources and Sustainability José Sánchez Labrador S.J. (IRNASUS-CONICET), School of Chemistry, Catholic University of Córdoba, Córdoba, Argentina.*

[‡] *Department of Chemistry, QUIAMM – INBIOTEC – CONICET, College of Exact and Natural Sciences, National University of Mar del Plata, Mar del Plata, Argentina.*

[§] *Faculty of Pharmacy, University of Ljubljana, Ljubljana, Republic of Slovenia.*

KEYWORDS *MDR reversing agents, P-glycoprotein, pinoresinol, diethylstilbestrol derivatives, structure-activity relationship, molecular docking.*

ABSTRACT: To find novel P-gp-inhibitors, a library of pregnane X receptor (PXR) ligands and the ZINC DrugsNow library were superimposed on the P-gp inhibitor (+)-pinoresinol (**1**) used as a query for a 3D similarity search. After determining the TanimotoCombo index of similarity with **1**, eight compounds from the PXR library and two ZINC compounds were selected for biological evaluation. The P-gp inhibition study showed that compounds **7**, **8** and **9** successfully increased intracellular doxorubicin (DOX) accumulation in the P-gp overexpressed Lucena 1 cells from 25, 12.5 and 6.25 μM , respectively. Among a series of analogs of **9**, compounds **26-30** were shown to be active, with **26** and **27** causing a significant increase in DOX accumulation from 1.56 μM and rendering Lucena 1 sensitive to DOX from 1.56 and 0.78 μM , respectively. Molecular modeling studies showed that both compounds bind to the P-gp at transmembrane helices (TMH) 4, 5 and 6, with **27** also showing contacts with TMH 3.

The development of drug resistance in cancer cells is a major barrier to successful chemotherapy. Among the various mechanisms behind multidrug resistance (MDR),¹ the increased energy-dependent efflux of a broad set of structurally unrelated cytostatic drugs is one of the most commonly encountered.² This phenomenon is mediated by transport proteins³, the best characterized of which is P-glycoprotein (P-gp) encoded by the *mdr-1* gene, one of the 49 identified ATP-binding cassette (ABC) transporters.⁴ P-gp contains two transmembrane domains, each consisting of six transmembrane α -helices (TMHs) and a nucleotide-binding domain (NBD).⁵ The latter hydrolyzes ATP to drive the transport of the binding substrate. The importance of P-gp is that it is expressed in almost half of human tumors², being observed in many types of leukemia,² including chronic myelogenous leukemia.⁶

Despite some encouraging results,⁷ most of the P-gp inhibitors submitted to clinical trials were disappointing, mainly due to their side effects, interactions with co-administered

drugs, or defects in the experimental design.^{8, 9} The development of drugs able to counteract the resistance mediated by P-gp is thus imperative. Natural compounds have attracted great attention and are considered fourth generation P-gp inhibitors.⁹ A preceding paper reported that the lignan (\pm)-pinoresinol, isolated from *Melia azedarach*,¹⁰ showed inhibitory activity on the transport of doxorubicin (DOX) out of P-gp overexpressed chronic myelogenous leukemia cells, Lucena 1 from 56 μM , as demonstrated by an accumulation assay.² By multidrug resistance reversal assay, (\pm)-pinoresinol was able to sensitize resistant cells to DOX from 7 μM .² Further studies revealed that (\pm)-pinoresinol bonds to P-gp through residues of the TMH 4, 5 and 6, some of which are also involved in the binding of the reference P-gp inhibitors, verapamil and tariquidar.²

This scenario and the success of plant-derived products as starting points for drug development¹¹ led us to search for suitable candidates with improved activity compared to (\pm)-

1 pinoresinol to specifically counteract the mechanism of drug
2 resistance in cells with enhanced P-gp expression. Since the
3 chemical structure of (+)-pinoresinol (**1**) (Figure 1) includes
4 two hydroxyl groups at a distance of 1.3 nm bound to a central
5 scaffold, we virtually screened our own previously synthesized
6 pregnane X receptor (PXR) library (Figure 1; compounds **2-9**),
7 which has a similar structural feature^{12, 13}, for similarity with **1**
8 using ROCS (ROCS 3.2.2.2: OpenEye Scientific Software,
9 Santa Fe, NM. <http://www.eyesopen.com>)¹⁴. TanimotoCombo
10 similarity index of shape (shape Tanimoto index) and
11 pharmacophore features (color Tanimoto index) of the query
12 and of compounds **2-9** was calculated. Additionally, the ZINC
13 DrugsNow library, containing more than 10 million
14 compounds, was also screened for three-dimensional similarity
15 to **1** using the TanimotoCombo similarity index (sum of shape
16 and color Tanimoto index).

17 ROCS demonstrated that the identified ZINC molecules **10-**
18 **25** (Figure 1) overlay better with **1** (TanimotoCombo between
19 1.413 and 1.606) than the bazedoxifene scaffold-based PXR
20 antagonists **2-6** (Figure 1, TanimotoCombo between 0.717 and
21 0.909) and the diethylstilbestrol scaffold-based PXR ligands **7-**
22 **9** (Figure 1, TanimotoCombo between 0.823 and 0.851) (see
23 Supporting Information for representative overlays, Figure S1).
24 On the basis of these results, the optimized structures of these
25 compounds were studied *in silico* by molecular docking, using
26 the human P-gp model previously built based on the
27 homologous P-gp from mouse (*Mus musculus*) as template.¹⁵ In
28 relevant cases, both stereoisomers (+/-) were investigated, and
29 both OH and NH tautomers (*keto* and *enol* forms) for lactam
30 compounds **20-25**. As observed in Table S1, the compounds
31 evaluated showed binding energies ranging from -7.07 to -9.23
32 kcal/mol. To have a first estimation of the ability to reverse the
33 P-gp-resistant phenotype of cancer cells, compounds **2-9**, the
34 most strongly binding non-tetrahydrofuran based ZINC
35 compound **23** (binding energy of NH-tautomer -9.23 kcal/mol)
36 and its close structural analog **21** (binding energy of OH-
37 tautomer -8.56 kcal/mol) were evaluated by a DOX
38 accumulation assay using flow cytometry² (see Supporting
39 Information). For this purpose, the chronic myelogenous
40 leukemia cells, Lucena 1,¹⁶ with 58% of the cells expressing P-
41 gp at the surface, were used as a model. These cells derived
42 from the sensitive K562 cell line with less P-gp in the outer
43 membrane (2% of cells). The retention of the cytotoxic clinical
44 drug DOX, a known P-gp fluorescent substrate, inside the cells
45 is commonly used to measure the capacity of a substance to
46 inhibit P-gp-mediated outward transport. Efflux inhibition
47 positively correlates with the intracellular concentration of the
48 probe.¹⁷ The same assay was carried out in the K562 cell line
49 with the aim of discarding any other synergism between the
50 compounds and the fluorescent drug different from the effect on
51 P-gp.

52 Notably, diethylstilbestrol-based PXR ligands **7, 8** and **9**
53 effectively increased intracellular DOX ($p < 0.05$) in Lucena 1
54 cells with Fluorescence Intensity Ratio (FIR) values
55 corresponding to 1.06, 1.19 and 1.16, respectively, at 25 μM ,
56 while the bazedoxifene PXR-antagonists **2-6** and the ZINC
57 compounds **21** and **23** did not enhance DOX-associated
58 fluorescence ($p > 0.05$) (Table 1). The activity of **7-9** was not
59 significantly different with respect to the activity of 25 μM of
60 the well-known reference P-gp modulators verapamil,
tamoxifen and cyclosporine A (CsA) ($p > 0.05$). It is worth

noting that **7-9** did not cause a significant increase in DOX
accumulation in the K562 cell line ($p > 0.05$) (Table S2)
indicating that these compounds specifically inhibited P-gp
transport. Taken together, the better reversal activity displayed
by **7-9** compared to that of **2-6** and **21** and **23** would indicate
that the diethylstilbestrol scaffold is more beneficial for
achieving P-gp inhibitory activity than the bazedoxifene- and
1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*b*]pyridin-6-one scaffold.

Following primary screening, and with the aim of
determining the minimum effective concentrations (MEC), **7-9**
were further tested at serial dilutions. As seen in Table 1,
compound **7** did not restore DOX accumulation in Lucena 1
cells at concentrations below 25 μM ($p > 0.05$), while **8** and **9**
turned out to be effective from 12.5 ($p < 0.01$) and 6.25 μM (p
< 0.001), respectively, with no differences in activity with
respect to verapamil, tamoxifen and CsA ($p > 0.05$). A dose-
dependent response was observed for **8** ($b = 0.0097$; $p = 0.0076$;
CI 95% = 0.0043 to 0.0151) and **9** ($b = 0.0090$; $p = 0.0496$;
CI 95% = 0.00002 to 0.01797). To the best of our knowledge, this
is the first report of the inhibition of diethylstilbestrol **7** on P-
gp-mediated transport, although inhibitory properties have been
previously reported against the breast cancer resistance protein
(BCRP) at 30 μM .¹⁸ In another work, **7** showed a weak
activation (45%) of P-gp ATPase activity at 10 μM .¹⁹ Although
mild stimulation of ATP hydrolysis may be associated with
modulatory activity on P-gp function, as observed for the
compound (\pm)-pinoresinol² or cyclosporine A,²⁰ no studies have
previously been performed about the inhibitory effect of **7** on
the P-gp-mediated efflux of drugs. Such investigations must be
carried out based on the assumption that some molecules able
to activate P-gp-ATPase, for instance the powerful modulator
tariquidar²¹ behave as inhibitors, while others, such as DOX,
vinblastine, progesterone or propranolol act only as
substrates.^{20, 22}

The limited clinical efficacy of multiple drugs as a result of
resistance is a complex mechanism not only attributed to the
efflux mediated by an ABC transporter.¹ It is therefore highly
beneficial to develop multi-targeted agents for overcoming the
resistance to pharmacotherapies.¹ As well as P-gp, PXR also
plays a key role in the MDR of cancer cells, acting as a
xenobiotic sensor that regulates the transcription of genes that
ultimately increase the activity of transporters and drug-
metabolizing enzymes.^{12, 13, 23} The dual activity of the PXR
antagonists **7** and **9** by negatively modulating PXR activity¹³
and, at the same time, the outward transport mediated by P-gp
are is encouraging as promising agents for overcoming MDR.

As previously reported, compound **7** was able to decrease P-
gp expression levels in MCF-7/MDR cells.²⁴ Therefore, the
effectiveness of this compound could be a sum of effects,
possibly inhibiting both P-gp transport and expression.

Given that compounds **7-9** displayed higher P-gp modulating
activity than (\pm)-pinoresinol², and aiming to optimize the P-gp-
mediated MDR reversal activity of the identified compounds,
an additional series of *O*-functionalized diethylstilbestrol
derivatives **26-34**, originally prepared as potential PXR
modulators (Figure 2), were assayed for P-gp inhibition at
progressive two-fold dilutions from 25 μM . Co-treatment of
Lucena 1 with **26-30** resulted in enhanced DOX accumulation
($p < 0.001-0.05$), with FIR values ranging from 1.04 to 1.32.
While **28-30** increased DOX-associated MFI from 3.12 μM (p

< 0.01-0.05), **26** and **27** were active from 1.56 μM ($p < 0.05$), with no differences with respect to the same concentrations of verapamil and CsA ($p > 0.05$) (Table 1 and Fig. S2A). Dose-dependency was observed for **26** ($b = 0.0082$; $p = 0.0106$; CI 95% = 0.0032 to 0.0133), **27** ($b = 0.0120$; $p = 0.0025$; CI 95% = 0.0071 to 0.0169), **28** ($b = 0.0071$; $p = 0.0109$; CI 95% = 0.0031 to 0.0110), **29** ($b = 0.0077$; $p = 0.0001$; CI 95% = 0.0068 to 0.0087) and **30** ($b = 0.0056$; $p = 0.0009$; CI 95% = 0.0009 to 0.0103). The lack of activity on K562 was confirmed indicating that the effect was due to P-gp inhibition (Table S2).

In addition to DOX accumulation study, a similar assay using the dye rhodamine 123 (Rho123), a classic P-gp substrate, was further carried out by flow cytometry As observed in Table S3 and Fig. S2B, compounds **26** and **27** increased the intracellular Rho123 as from 50 μM and 12.5 μM , respectively, and were significantly different from verapamil and CsA both at 25 and 12.5 μM , respectively ($p < 0.05$), but were comparable with tamoxifen at the same concentrations ($p > 0.05$).

To evaluate the capabilities of the most effective compounds, **26** and **27**, more thoroughly, a multidrug resistance reversal assay was carried out (see Supporting Information). The different parameters measured by both types of technique allowed us to address different aspects related to their pharmacological profile to determine the effectiveness of the compounds.²⁵ The accumulation assay enables assessment of the quantity of substrate accumulated inside the cells resulting from inhibition of the efflux, while the multidrug resistant reversal assay determines the intracellular activity of a cytotoxic drug applied in combination with P-gp modulators compared with its individual activity.² It is worth mentioning that Lucena 1 cells displayed 34-fold more resistance to DOX toxicity than parental K562 cells, with IC_{50} values of 48.49 ± 3.8 and 1.42 ± 0.18 μM , respectively. As expected, **26** and **27** showed their ability to reverse the P-gp-mediated DOX resistance from 1.56 and 0.78 μM , respectively (Table 1 and Figure 3), displaying fold reversal (FR) values of 1.30 and 1.16 ($p < 0.05$), respectively (Table 1). These results match those found in the accumulation assay. To determine whether the DOX cytotoxicity restoring effect was specific to P-gp, K562 cells were treated with 3.12-0.78 μM of **26** or **27**. No sensitization to DOX on K562 was observed with compound **26** at 3.12 μM , while **27** was not able to increase DOX toxicity in these cells at 1.56 (Table S2, Supporting Information). These results showed that both molecules appear as chemosensitizers specific to P-gp modulation.

As previously mentioned by Syed et al.,²⁶ P-gp modulators submitted to clinical trials present octanol/water partition coefficients ranging from 3.64 to 6.81. The partition coefficients (CLogP, calculated with ChemDraw Ultra software) found for compounds **7-9** and **26-30** are mostly in agreement with these values (see Table S4, Supporting Information) suggesting that the assayed compounds show a similar partition into the lipid bilayer to that observed with the anti-P-gp candidates. In addition, the ClogP values obtained are higher than 2.92/3.25, the minimum ClogP values established for a compound to be considered as an effective P-gp inhibitor.^{27, 28} In the present work, the most potent compounds **26-30** showed the highest calculated logP values (5.17 to 7.22, Table S4) in agreement with many authors^{20, 29, 30} who proposed that lipophilicity is a key factor for a better inhibition of P-gp.

The binding mode of **1** was previously described,² with the main contacts occurring with residues S222, A223, K234, F303, Y307, Y310, L339, A342 and F343, most of which are amino acids from TMH 4, 5 and 6 at the top of the inverted "V" shaped by the transmembrane α -helices. All these residues were proposed as essential for binding on theoretical and experimental bases, as previously stated.^{2, 15} The inhibitors **7-9** and **26-30**, which were found active by DOX accumulation assay and by docking, overlap their binding regions with that of the parent compound **1**, which in turn overlaps with the reference inhibitor tariquidar.² In particular, compounds **26**, **27** and **30** showed the maximum superposition with tariquidar, with **27** being the only compound of the **26-30** series which also showed contacts with TMH 3 (T199, F200 and G203). The superimposition of **1**, **26** and **27** with tariquidar is shown in Figure 4. Further details on the binding mode of **26** and **27** are available in Supporting Information, Figs. S3-S4. One of the most plausible reason behind the difference in activity of **26** and **27** with respect to DOX and Rho123 accumulation techniques, which was also observed in treatments with (\pm) pinoresinol,² concerns to the affinity of each substrate to the binding sites of P-gp. This issue may be explained based on the results obtained by performing docking studies. The lowest energy docked poses of both **26** and **27** bind to the two main sites of DOX, the latter with -8.23 and -8.16 kcal/mol binding energies (Fig. S5). As shown in Fig S5, also other higher energy conformations of **26** and **27** (up to 1.2 kcal/mol above the lowest one) overlapped these sites as well. However, none of these conformations are able to overlap the primary and one of the secondary sites of Rho123 (which have similar affinities within 0.3 kcal/mol), as illustrated in Fig S6 and Fig. S7. Clearly, neither **26** nor **27** would be able to inhibit the Rho123 efflux (at least not in the same competitive way) as it does with DOX. In sharp contrast, the much more flexible and bigger molecule CsA binds in a region that occlude the three main Rho123 binding sites (binding energies -10.0 to -9.0 kcal/mol), as shown in Figure S8. Although smaller than CsA, verapamil still showed a similar pattern (Fig. S9, conformations from -9.1 to -8.1 kcal/mol shown) These differences in the binding preferences of both target compounds, of the two model substrates and of the reference inhibitors are consistent with the experimental observations regarding the preference of **26** and **27**, and also of tamoxifen, for DOX, whereas CsA and verapamil showed a similar behavior with Rho123 or DOX as substrates.

While compounds **9**, **26** and **27**, differing only in the length of the hydroxyalkoxy side chains (2 to 4 carbon atoms), appear as encouraging lead compounds for P-gp inhibition, the sulphate ester derivatives **32-34** had no effect. As observed in Table 1, the increase in the length of the side chain in **26-27** with respect to **9** enhanced effectiveness. On the other hand, the addition of an O-acetyl group in the side chain (compounds **29-30**) decreased the activity compared to the hydroxy compounds **26-27**. The presence of O-CH₃ groups at positions 4 and 4' of compound **8** slightly increased P-gp modulation activity with respect to bis-hydroxy compound **7**, while the addition of the 2-hydroxyethyl group in the lateral chain of **7** to give **9** markedly increased the MDR-modulating efficiency.

To further determine the suitability of compounds **26** and **27** as potential inhibitors of P-gp function, their toxicity on non-tumoral peripheral blood mononuclear cells (PBMC) was evaluated. With an MTT assay,^{31, 32} **26** and **27** showed $34.67 \pm$

0.88 and $41.00 \pm 0.58\%$ cytotoxicity at $25 \mu\text{M}$, while a complete absence of toxicity was observed at $6.25 \mu\text{M}$. A compound can be considered as cytotoxic when the IC_{50} values are lower than $10 \mu\text{M}$.³³

With these results, the newly identified compounds **26-27**, appear as promising starting points for the development of inhibitors of the P-gp-mediated transport of chemotherapeutic drugs such as DOX. The information obtained about the structural requirements for activity sheds light on the design of further synthetic pinoresinol-related agents able to reverse the MDR/P-gp phenotype.




Figure 1. Chemical structures of (+)-pinoresinol (**1**), the PXR ligands **2-9** and the ZINC compounds **10-25** showing high similarity with **1** by ROCS analysis.




Figure 2. Chemical structures of the diethylstilbestrol derivatives: **26-34**.




Figure 3. Dose-response curves for cytotoxicity of doxorubicin (DOX) in Lucena 1 and K562 cells with and without compounds **26** (A) and **27** (B) as determined by the multidrug resistance reversal assay. Values are expressed as mean \pm SE of at least three independent experiments.




Figure 4. (A) Superimposition of the lowest energy poses of the inhibitors **1** (highlighted in red), **26** (in yellow), **27** (in violet) and the reference inhibitor tariquidar (in green). (B) Binding of the most active compound **27** (balls and sticks) showing its main contacts (licorice). The cartoon representation of the α -helices is colored according to the sequence, from TMH 1 (red) to TMH 12 (blue).

ASSOCIATED CONTENT

Supporting Information

The associated PDF contains detailed experimental procedures and biological assays, summary of docking results for PXR ligands and ZINC compounds (Table S1), effect of PXR and ZINC compounds on P-gp function in the K562 cell line by DOX accumulation assay (Table S2), effect of **26** and **27** on P-gp function by rhodamine 123 accumulation assay (Table S3), ClogP values (Table S4), overlays of PXR-ligands and ZINC compounds with **1** according to ROCS (Figure S1), representative histograms of DOX and Rho 123 accumulation

assays (Figure S2) and poses of binding to P-gp of the most active compounds determined by docking (Figure S3-S9).

The Supporting Information is available free of charge on the ACS Publications website.

AUTHOR INFORMATION

Corresponding Author

* María Cecilia Carpinella, Laboratorio de Química Fina y Productos Naturales, Facultad de Ciencias Químicas, Universidad Católica de Córdoba, Avda. Armada Argentina 3555, X5016DHC, Córdoba, Argentina. Tel: 54 351-4938000, Ext 611. Fax: 54 351-4938061.

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Funding Sources

This research project was conducted with the support of the Catholic University of Córdoba, CONICET (PIP 11220130100437), FONCyT (PICT 2014-1594), MINCyT-MHEST AR/1408, and of the Slovenian Research Agency

(Grant No. P1-0208; Bilateral project Slovenia – Argentina ARRS-BI-AR/15-17-008).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

We thank Joss Heywood for revising the English language. M.C. Carpinella, D.M.A. Vera, and S.M. Palacios are staff members of the National Research Council of Argentina (CONICET). JL acknowledges receipt of a Scholarship from CONICET. We thank OpenEye Scientific Software, Santa Fe, NM, for free academic licenses for the use of their software.

ABBREVIATIONS

BCRP, breast cancer resistance protein; CLog P, calculated octanol: water partition coefficient; DOX, doxorubicin; FR, fold reversal; FIR, fluorescence intensity ratio; MEC, minimum effective concentration; MFI, medium fluorescence intensity; PBMC, peripheral blood mononuclear cells; P-gp, P-glycoprotein; PXR, pregnane X receptor; Rho123, rhodamine 123.

Table 1. Effect of PXR and selected ZINC compounds on P-gp function by doxorubicin accumulation and resistance reversal assays in Lucena 1 cell line

Compound	FIR/FR										
	Concentration (μM)										
	25	12.50	6.25	3.12	1.56	0.78	0.39	0.19	0.098	0.048	0.024
2	0.80 ± 0.02										
3	0.72 ± 0.03										
4	0.75 ± 0.08										
5	1.01 ± 0.03										
6	0.90 ± 0.15										
7	1.06 ± 0.01*	1.10 ± 0.08	1.04 ± 0.03								
8	1.19 ± 0.03*	1.09 ± 0.02**	1.09 ± 0.07								
9	1.16 ± 0.08*	1.20 ± 0.04*	1.08 ± 0.007***	1.01 ± 0.06							
21	1.11 ± 0.06										
23	0.96 ± 0.01										
26	1.23 ± 0.08*	1.06 ± 0.02*	1.09 ± 0.01*	1.04 ± 0.009*/	1.05 ± 0.003*/	0.98 ± 0.02/					
				1.55 ± 0.09**	1.30 ± 0.12*	1.15 ± 0.11					
27	1.32 ± 0.12*	1.18 ± 0.07*	1.08 ± 0.02*	1.06 ± 0.01*/	1.10 ± 0.02*/	0.99 ± 0.02/	1.00 ± 0.02/				
				1.61 ± 0.14*	1.34 ± 0.07*	1.16 ± 0.08*	1.03 ± 0.03				
28	1.21 ± 0.07*	1.15 ± 0.05*	1.12 ± 0.02**	1.07 ± 0.009**	1.03 ± 0.03						
29	1.21 ± 0.03***	1.10 ± 0.02*	1.06 ± 0.02*	1.04 ± 0.01*	1.02 ± 0.01						
30	1.18 ± 0.07*	1.10 ± 0.02*	1.09 ± 0.03**	1.08 ± 0.02*	1.01 ± 0.02						
31	0.99 ± 0.04										
32	1.04 ± 0.05										
33	1.03 ± 0.02										
34	0.95 ± 0.06										
Ver	1.35 ± 0.009***	1.26 ± 0.03**	1.20 ± 0.06*	1.16 ± 0.03*	1.07 ± 0.03*	1.07 ± 0.07					

Tam	1.13 ± 1.03*	1.07 ± 0.02*	1.05 ± 0.01*	1.01 ± 0.02							
CsA	1.40 ± 0.01*	1.47 ± 0.12*	1.44 ± 0.06**	1.47 ± 0.07**	1.46 ± 0.12*	1.43 ± 0.09*	1.30 ± 0.04**	1.25 ± 0.06*	1.16 ± 0.04*	1.15 ± 0.01**	1.01 ± 0.04

Ver: verapamil. Tam: tamoxifen. CsA: cyclosporine A. Fluorescence Intensity Ratio (FIR); analysis of differences between the intracellular accumulations of DOX in cells treated with the tested compounds compared to control cells were performed by one-tailed paired *t*-test. Fold Reversal (FR) values were calculated as IC₅₀ of DOX alone/IC₅₀ of DOX in the presence of the tested compounds. Statistical comparisons between IC₅₀ of DOX alone or with compound in each treatment were performed by one-tailed paired *t*-test. Results represent the mean ± SE. ****p* < 0.001, ***p* < 0.01 and **p* < 0.05.

REFERENCES

- (1) Chen, Y.; Tang, Y.; Guo, C.; Wang, J.; Boral, D.; Nie, D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. *Biochem. Pharmacol.* **2012**, *83*, 1112-1126.
- (2) González, M. L.; Vera, D. M. A.; Laiolo, J.; Joray, M. B.; Maccioni, M.; Palacios, S. M.; Molina, G.; Lanza, P. A.; Gancedo, S.; Rumjanek, V.; Carpinella, M. C. Mechanism Underlying the Reversal of Drug Resistance in P-Glycoprotein-Expressing Leukemia Cells by Pinorelinol and the Study of a Derivative. *Front. Pharmacol.* **2017**, *8*.
- (3) Chen, Z.; Shi, T.; Zhang, L.; Zhu, P.; Deng, M.; Huang, C.; Hu, T.; Jiang, L.; Li, J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. *Cancer Lett.* **2016**, *370*, 153-164.
- (4) Palmeira, A.; Sousa, E.; H Vasconcelos, M.; M Pinto, M. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. *Curr. Med. Chem.* **2012**, *19*, 1946-2025.
- (5) Loo, T. W.; Clarke, D. M. Thiol-reactive drug substrates of human P-glycoprotein label the same sites to activate ATPase activity in membranes or dodecyl maltoside detergent micelles. *Biochem. Biophys. Res. Commun.* **2017**, *488*, 573-577.
- (6) Rumjanek, Vivian M.; Vidal, Raphael S.; Maia, Raquel C. Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines? *Biosci. Rep.* **2013**, *33*, e00081.
- (7) List, A. F.; Kopecky, K. J.; Willman, C. L.; Head, D. R.; Persons, D. L.; Slovák, M. L.; Dorr, R.; Karanes, C.; Hynes, H. E.; Doroshov, J. H.; Shurafa, M.; Appelbaum, F. R. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. *Blood* **2001**, *98*, 3212-3220.
- (8) Szakács, G.; Hall, M. D.; Gottesman, M. M.; Boumendjel, A.; Kachadourian, R.; Day, B. J.; Baubichon-Cortay, H.; Di Pietro, A. Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance. *Chem. Rev.* **2014**, *114*, 5753-5774.
- (9) Silva, R.; Vilas-Boas, V.; Carmo, H.; Dinis-Oliveira, R. J.; Carvalho, F.; de Lourdes Bastos, M.; Remião, F. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. *Pharmacol. Ther.* **2015**, *149*, 1-123.
- (10) Carpinella, M. C.; Giorda, L. M.; Ferrayoli, C. G.; Palacios, S. M. Antifungal Effects of Different Organic Extracts from *Melia azedarach* L. on Phytopathogenic Fungi and Their Isolated Active Components. *J. Agric. Food Chem.* **2003**, *51*, 2506-2511.
- (11) Carpinella, M. C.; Rai, M. *Novel therapeutic agents from plants*; Science publishers, 2009.
- (12) Hodnik, Ž.; Peterlin Mašič, L.; Tomašič, T.; Smodiš, D.; D'Amore, C.; Fiorucci, S.; Kikelj, D. Bazedoxifene-Scaffold-Based Mimetics of Solomonsterols A and B as Novel Pregnane X Receptor Antagonists. *J. Med. Chem.* **2014**, *57*, 4819-4833.
- (13) Hodnik, Ž.; Tomašič, T.; Smodiš, D.; D'Amore, C.; Mašič, L. P.; Fiorucci, S.; Kikelj, D. Diethylstilbestrol-scaffold-based pregnane X receptor modulators. *Eur. J. Med. Chem.* **2015**, *103*, 551-562.
- (14) Hawkins, P. C. D.; Skillman, A. G.; Nicholls, A., Comparison of Shape-Matching and Docking as Virtual Screening Tools. *J. Med. Chem.* **2007**, *50*, 74-82.
- (15) Jara, G. E.; Vera, D. M. A.; Pierini, A. B. Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study. *J. Mol. Graph. Modeling* **2013**, *46*, 10-21.
- (16) Moreira, M. A. M.; Bagni, C.; de Pinho, M. B.; Mac-Cormick, T. M.; dos Santos Mota, M.; Pinto-Silva, F. E.; Daflon-Yunes, N.; Rumjanek, V. M. Changes in gene expression profile in two multidrug resistant cell lines derived from a same drug sensitive cell line. *Leuk. Res.* **2014**, *38*, 983-987.
- (17) Castagnolo, D.; Contemori, L.; Maccari, G.; Avramova, S. I.; Neri, A.; Sgaragli, G.; Botta, M. From Taxuspine X to Structurally Simplified Taxanes with Remarkable P-Glycoprotein Inhibitory Activity. *ACS Med. Chem. Lett.* **2010**, *1*, 416-421.
- (18) Sugimoto, Y.; Tsukahara, S.; Imai, Y.; Sugimoto, Y.; Ueda, K.; Tsuruo, T. Reversal of Breast Cancer Resistance Protein-mediated Drug Resistance by Estrogen Antagonists and Agonists. *Mol. Cancer Ther.* **2003**, *2*, 105-112.
- (19) Rao, U. S.; Fine, R. L.; Scarborough, G. A. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. *Biochem. Pharmacol.* **1994**, *48*, 287-292.
- (20) Seelig, A.; Landwojtowicz, E. Structure-activity relationship of P-glycoprotein substrates and modifiers. *Eur. J. Pharm. Sci.* **2000**, *12*, 31-40.
- (21) Loo, T. W.; Clarke, D. M. Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformation. *Biochem. Pharmacol.* **2014**, *92*, 558-566.
- (22) Watanabe, T.; Kokubu, N.; Charnick, S. B.; Naito, M.; Tsuruo, T.; Cohen, D. Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein. *Br. J. Pharmacol.* **1997**, *122*, 241 - 248.
- (23) Kong, Q.; Han, Z.; Zuo, X.; Wei, H.; Huang, W. Co-expression of pregnane X receptor and ATP-binding cassette sub-family B member 1 in peripheral blood: A prospective indicator for drug resistance prediction in non-small cell lung cancer. *Oncol. Lett.* **2016**, *11*, 3033-3039.
- (24) Mutoh, K.; Tsukahara, S.; Mitsuhashi, J.; Katayama, K.; Sugimoto, Y. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. *Cancer Sci.* **2006**, *97*, 1198-1204.
- (25) Férté, J.; Kühnel, J.-M.; Chapuis, G.; Rolland, Y.; Lewin, G.; Schwaller, M. A. Flavonoid-Related Modulators of Multidrug Resistance: Synthesis, Pharmacological Activity, and Structure-Activity Relationships. *J. Med. Chem.* **1999**, *42*, 478-489.
- (26) Syed, S. B.; Arya, H.; Fu, I.-H.; Yeh, T.-K.; Periyasamy, L.; Hsieh, H.-P.; Coumar, M. S. Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer. *Sci. Rep.* **2017**, *7*, 7972.
- (27) Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. *J. Clin. Phar. Ther.* **2003**, *28*, 203-228.
- (28) Li, D.; Chen, L.; Li, Y.; Tian, S.; Sun, H.; Hou, T. ADMET Evaluation in Drug Discovery. 13. Development of in Silico Prediction Models for P-Glycoprotein Substrates. *Mol. Pharm.* **2014**, *11*, 716-726.
- (29) Zamora, J. M.; Pearce, H.; Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. *Mol. Pharmacol.* **1988**, *33*, 454-462.
- (30) Pearce, H.; Winter, M.; Beck, W. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. *Adv. Enzyme Regul.* **1990**, *30*, 357-373.
- (31) González, M. L.; Joray, M. B.; Laiolo, J.; Crespo, M. I.; Palacios, S. M.; Ruiz, G. M.; Carpinella, M. C. Cytotoxic Activity of Extracts from Plants of Central Argentina on Sensitive and Multidrug-Resistant Leukemia Cells: Isolation of an Active Principle from *Gaillardia megapotamica*. *Evid. Based Complement. Alternat. Med.* **2018**, *2018*.
- (32) Joray, M. B.; Trucco, L. D.; González, M. L.; Diaz Napal, G. N.; Palacios, S. M.; Bocco, J. L.; Carpinella, M. C. Antibacterial and Cytotoxic Activity of Compounds Isolated from *Flourensia oolepis*. *Evid. Based Complement. Alternat. Med.* **2015**, *2015*, 11.
- (33) Mayer, C. D.; Bracher, F. Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone. *Eur. J. Med. Chem.* **2011**, *46*, 3227-3236.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60